Uvantis Therapeutics has filed a notice of an exempt offering of securities to raise $5 Million in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Uvantis Therapeutics is raising up to $5 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Uvantis Therapeutics
We aim to revolutionize the treatment of Catheter-Associated Urinary Tract Infections (CAUTI). Our focus is on developing patient-centric, innovative solutions that minimize antibiotic use, preserve the bladder’s natural microbiome (the urobiome), and promote bladder health.

To learn more, visit https://uvantis.com/
LinkedIn: https://www.linkedin.com/company/uvantis/home/

Contact:
Paul Giannasca, Senior Executive

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.